Feedback
Settings

Settings

Goto Application

233,078 results
Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 23,308
1.20210315935TREATMENT OF VON WILLEBRAND DISEASE
US - 14.10.2021
Int.Class A61K 35/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
19Platelets; Megacaryocytes
 Appl.No 17166490 Applicant Cellphire, Inc. Inventor Keith Andrew Moskowitz

Provided herein are methods and compositions for treating von Willebrand disease with platelets, platelet derivatives, and/or thrombosomes.

2.WO/2021/206183FUNCTIONAL POLYPEPTIDES AND USE THEREOF
WO - 14.10.2021
Int.Class C12N 15/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
 Appl.No PCT/JP2021/015369 Applicant NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY Inventor SAKAI, Ryuichi
A polypeptide that comprises the amino acid sequence of SEQ ID NO: 1 and has a function of delivering a substance into cells, a polypeptide that comprises the amino acid sequence of SEQ ID NO: 2 and has a function of degrading a nucleic acid molecule, a polypeptide that comprises the amino acid sequence of SEQ ID NO: 3 and has a function of degrading a nucleic acid molecule and a function of intranuclearly migrating the same, polynucleotides encoding the respective polypeptides, and transformed cells containing the respective polynucleotides.
3.WO/2021/204279PROBIOTIC COMPOSITION FOR TREATING RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER, FORMULATION AND USE
WO - 14.10.2021
Int.Class A61K 35/747
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
741Probiotics
744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
747Lactobacilli, e.g. L. acidophilus or L. brevis
 Appl.No PCT/CN2021/086312 Applicant BEIJING FRIENDSHIP HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIVERSITY Inventor TUO, Houzhen
A probiotic composition for treating rapid eye movement sleep behavior disorder, being prepared from Bacillus licheniformis, Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis, and pharmaceutically acceptable adjuvants. The probiotic composition can improve the symptoms of rapid eye movement sleep behavior disorder of a patient, improve RBD symptoms of idiopathic RBD patients and PD patients, and reduce the dosage of levodopa in PD patients.
4.WO/2021/206589COMPOSITION FOR THE PREVENTION OR TREATMENT OF ENDOTHELIAL DYSFUNCTION
WO - 14.10.2021
Int.Class A61K 35/618
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
56Materials from animals other than mammals
618Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
 Appl.No PCT/RU2021/050094 Applicant SOLOVYEV, Nikolay Vladimirovich Inventor SOLOVYEV, Nikolay Vladimirovich
The use of a composition comprising a hydrolysate obtained by acidic and/or enzymatic hydrolysis of one or more biological resources selected from the group including bivalve mollusks, annelids, leeches; and water, for the prevention or treatment of endothelial dysfunction (ED) and/or an ED-related disease or condition in a mammal in need of such treatment or prevention.
5.20210315793COMPOSITIONS FOR PROTECTING SKIN COMPRISING DNA REPAIR ENZYMES AND PHYCOBILIPROTEIN
US - 14.10.2021
Int.Class A61K 8/66
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
30containing organic compounds
64Proteins; Peptides; Derivatives or degradation products thereof
66Enzymes
 Appl.No 17340172 Applicant ALGAKTIV, S.L. Inventor Eugenia RUIZ CANOVAS

The invention relates to compositions for repairing the adverse effects of the environment daily stress, sun exposure or premature-aging on human skin which comprise a DNA repair enzyme and a phycobiliprotein.

6.20210315933COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING TARGET SPECIFIC FUSION PROTEINS
US - 14.10.2021
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
 Appl.No 17261823 Applicant TCR2 THERAPEUTICS INC. Inventor Patrick Alexander Baeuerle

Provided herein are T cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more MUC16 or IL 13Rα2 or MSLN TFPs, and methods of use thereof for the treatment of diseases, including cancer.

7.20210315227STABILIZED COMPOSITIONS CONTAINING EDIBLE OIL AND THEIR USES IN FOOD PRODUCTS
US - 14.10.2021
Int.Class A23D 9/06
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
DEDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
9Other edible oils or fats, e.g. shortenings, cooking oils
06Preservation of finished products
 Appl.No 17271733 Applicant ROQUETTE FRERES Inventor Bernard PORA

The present invention relates to a composition comprising:

    • (i) from 10 to 40% by weight, preferably from 20 to 30% by weight of an edible oil;
    • (ii) lactose and
    • (iii) mannitol

wherein the edible oil comprises at least 20% by weight, preferably between 25 and 40% by weight, typically 30 and 35% by weight of polyunsaturated fatty acids and the weight ratio of lactose to mannitol is from 1:3 to 3:1, preferably between 1:2 to 2:1, more preferably 1:1.

8.20210317184T CELL MODIFICATION
US - 14.10.2021
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
 Appl.No 17272865 Applicant GlaxoSmithKline Intellectual Property Devolopment Limited Inventor Sara Jane BRETT

Improved compositions and methods for treating diseases, such as cancer, by providing a cell immunotherapy, wherein the cell immunotherapy is an immunomodulatory cell expressing an exogenous CD8 co-receptor and a modified T cell receptor (TCR) are provided. Also provided are polynucleotides, expression vectors, and immunomodulatory cells including the immunotherapy, as well as methods of generating said immunomodulatory cells.

9.WO/2021/204198CHIMERIC POLYPEPTIDE AND USE THEREOF
WO - 14.10.2021
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No PCT/CN2021/085946 Applicant CURE GENETICS CO., LTD Inventor HUANG, Zhuo
Provided is a chimeric polypeptide comprising a truncated HLA-E heavy chain, a hinge domain, a transmembrane domain, and an intracellular activation signal domain derived from a non-HLA-E heavy chain, wherein the intracellular activation signal domain comprises a co-stimulatory domain derived from a co-stimulatory molecule and/or a signaling domain derived from a primary signaling molecule.
10.WO/2021/207483MICRONEEDLE ARRAY DELIVERY OF ADENOVIRUS VECTORED VACCINES WITH AND WITHOUT ADJUVANTS
WO - 14.10.2021
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
 Appl.No PCT/US2021/026364 Applicant UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor FALO, Louis, Jr.
Provided herein are microneedle array devices for delivery of recombinant adenovirus particles, methods of making the devices, and used for the devices. The microneedle array devices are storage-stable at 4ºC, retaining adenovirus infectivity for at least one month.
# -